Key TakeawaysUniversal semaglutide access could reduce all-cause mortality by 7.41%, saving 28 million lives over five years.The study projects a 21.9% decrease in global obesity prevalence, equating to 330 million fewer people with obesity.Obesity reduction significantly impacts mortality by decreasing risks for cardiovascular and chronic kidney diseases.The study emphasizes the need for policy discussions on […]
